136 related articles for article (PubMed ID: 17956695)
1. [Inhibition of L-arginine and cilostazol on activation of platelets in vitro].
Zhou J; Liu JH; Xing YC; Wang DM; Ouyang XL
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Oct; 15(5):1079-83. PubMed ID: 17956695
[TBL] [Abstract][Full Text] [Related]
2. Loading solution prevents activation damage of human platelets before lyophilization.
Zhou J; Zhang C; Liu J; Fan L; Yang L
Cryobiology; 2011 Dec; 63(3):229-34. PubMed ID: 21945819
[TBL] [Abstract][Full Text] [Related]
3. [Inhibiting effect of adenosine on platelet activation in vitro].
Wang DM; Liu JH; Zhou J; Ouyang XL; Xing YC
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Dec; 13(6):1094-8. PubMed ID: 16403288
[TBL] [Abstract][Full Text] [Related]
4. Cilostazol inhibits platelet-leukocyte interaction by suppression of platelet activation.
Ito H; Miyakoda G; Mori T
Platelets; 2004 Aug; 15(5):293-301. PubMed ID: 15370100
[TBL] [Abstract][Full Text] [Related]
5. Cilostazol inhibits the expression of activation-dependent membrane surface glycoprotein on the surface of platelets stimulated in vitro.
Inoue T; Sohma R; Morooka S
Thromb Res; 1999 Feb; 93(3):137-43. PubMed ID: 10030830
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet aggregation and the release of P-selectin from platelets by cilostazol.
Kariyazono H; Nakamura K; Shinkawa T; Yamaguchi T; Sakata R; Yamada K
Thromb Res; 2001 Mar; 101(6):445-53. PubMed ID: 11323002
[TBL] [Abstract][Full Text] [Related]
7. Relationships between optical aggregometry (type born) and flow cytometry in evaluating ADP-induced platelet activation.
Sbrana S; Della Pina F; Rizza A; Buffa M; De Filippis R; Gianetti J; Clerico A
Cytometry B Clin Cytom; 2008 Jan; 74(1):30-9. PubMed ID: 17630652
[TBL] [Abstract][Full Text] [Related]
8. [Protective effects of DMSO on function of lyophilized human platelets].
Zhou J; Liu JH; Jin Y; Ouyang XL; Yang LG
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1284-8. PubMed ID: 18088485
[TBL] [Abstract][Full Text] [Related]
9. Effect of glycoprotein IIb/IIIa inhibitors on CD62p expression, platelet aggregates, and microparticles in vitro.
Matzdorff AC; Kühnel G; Kemkes-Matthes B; Pralle H; Voss R; Fareed J
J Lab Clin Med; 2000 Mar; 135(3):247-55. PubMed ID: 10711863
[TBL] [Abstract][Full Text] [Related]
10. Salvianolic acid a inhibits platelet activation and aggregation in patients with type 2 diabetes mellitus.
Zhou AM; Xiang YJ; Liu EQ; Cai CH; Wu YH; Yang LB; Zeng CL
BMC Cardiovasc Disord; 2020 Jan; 20(1):15. PubMed ID: 31931718
[TBL] [Abstract][Full Text] [Related]
11. PPACK-thrombin inhibits thrombin-induced platelet aggregation and cytoplasmic acidification but does not inhibit platelet shape change.
Greco NJ; Tenner TE; Tandon NN; Jamieson GA
Blood; 1990 May; 75(10):1989-90. PubMed ID: 2337670
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells.
Tada T; Aki K; Oboshi W; Kawazoe K; Yasui T; Hosoi E
Drug Des Devel Ther; 2016; 10():3099-3107. PubMed ID: 27713620
[TBL] [Abstract][Full Text] [Related]
13. Cilostazol inhibits leukocyte integrin Mac-1, leading to a potential reduction in restenosis after coronary stent implantation.
Inoue T; Uchida T; Sakuma M; Imoto Y; Ozeki Y; Ozaki Y; Hikichi Y; Node K
J Am Coll Cardiol; 2004 Oct; 44(7):1408-14. PubMed ID: 15464320
[TBL] [Abstract][Full Text] [Related]
14. Thrombin-induced platelet activation and its inhibition by anticoagulants with different modes of action.
Nylander S; Mattsson C
Blood Coagul Fibrinolysis; 2003 Feb; 14(2):159-67. PubMed ID: 12632026
[TBL] [Abstract][Full Text] [Related]
15. Combined aspirin and cilostazol treatment is associated with reduced platelet aggregation and prevention of exercise-induced platelet activation.
Cleanthis M; Bhattacharya V; Smout J; Ashour H; Stansby G
Eur J Vasc Endovasc Surg; 2009 May; 37(5):604-10. PubMed ID: 19297212
[TBL] [Abstract][Full Text] [Related]
16. Effect of remnant-like particle on shear-induced platelet activation and its inhibition by antiplatelet agents.
Yamazaki M; Uchiyama S; Xiong Y; Nakano T; Nakamura T; Iwata M
Thromb Res; 2005; 115(3):211-8. PubMed ID: 15617744
[TBL] [Abstract][Full Text] [Related]
17. Lack of uniform platelet activation in patients after ischemic stroke and choice of antiplatelet therapy.
Serebruany VL; Malinin AI; Oshrine BR; Sane DC; Takserman A; Atar D; Hennekens CH
Thromb Res; 2004; 113(3-4):197-204. PubMed ID: 15140583
[TBL] [Abstract][Full Text] [Related]
18. Platelet function alterations and their relation to P-selectin (CD62P) expression in children with iron deficiency anemia.
Yıldırım ZK; Orhan MF; Büyükavcı M
Blood Coagul Fibrinolysis; 2011 Mar; 22(2):98-101. PubMed ID: 21245745
[TBL] [Abstract][Full Text] [Related]
19. [The effects of post coronary stenting triple antiplatelet therapies on platelet functions].
Han YL; Su QF; Li Y; Kang J; Yan CH; Wang SL
Zhonghua Nei Ke Za Zhi; 2006 Aug; 45(8):635-8. PubMed ID: 17074146
[TBL] [Abstract][Full Text] [Related]
20. Regulation of CD40L (CD154) and CD62P (p-selectin) surface expression upon GPIIb-IIIa blockade of platelets from stable coronary artery disease patients.
Chandler AB; Earhart AD; Speich HE; Kueter TJ; Hansen J; White MM; Jennings LK
Thromb Res; 2010 Jan; 125(1):44-52. PubMed ID: 19487018
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
